Allergy Therapeutics PLC Director/PDMR Shareholding (8300K)
September 26 2016 - 6:59AM
UK Regulatory
TIDMAGY
RNS Number : 8300K
Allergy Therapeutics PLC
26 September 2016
26 September 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Director/PDMR Shareholding
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, announces
that on 26 September 2016, the Board of Allergy Therapeutics was
informed that today Manuel Llobet, Chief Executive Officer,
purchased 100,000 ordinary shares of 0.10p in the Company
("Ordinary Shares") at a price of 18.0 pence per Ordinary Share. Mr
Llobet's beneficial holding now stands at 3,275,000 Ordinary
Shares, which represents 0.56% of the issued share capital of the
Company to which voting rights are attached.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Peter Steel / Duncan Monteith, Corporate
Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura
Thornton
allergytherapeutics@consilium-comms.com
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBGGDCCUDBGLL
(END) Dow Jones Newswires
September 26, 2016 06:59 ET (10:59 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024